Jim Simons’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.94M | Sell |
58,300
-32,600
| -36% | -$1.98M | 0.01% | 1585 |
|
|
2026
Q1 | $5.04M | Buy |
90,900
+14,600
| +19% | +$786K | 0.01% | 1378 |
|
|
2025
Q4 | $3.7M | Sell |
76,300
-47,000
| -38% | -$1.83M | 0.01% | 1501 |
|
|
2025
Q3 | $3.78M | Sell |
123,300
-139,786
| -53% | -$3.21M | 0.01% | 1654 |
|
|
2025
Q2 | $5.84M | Sell |
263,086
-75,614
| -22% | -$1.58M | 0.01% | 1424 |
|
|
2025
Q1 | $6.3M | Buy |
338,700
+145,500
| +75% | +$2.43M | 0.01% | 1279 |
|
|
2024
Q4 | $2.56M | Sell |
193,200
-7,200
| -4% | -$174K | ﹤0.01% | 1887 |
|
|
2024
Q3 | $6.71M | Buy |
200,400
+47,698
| +31% | +$1.63M | 0.01% | 1265 |
|
|
2024
Q2 | $3.83M | Buy |
152,702
+52,502
| +52% | +$1.22M | 0.01% | 1474 |
|
|
2024
Q1 | $2.26M | Buy |
100,200
+4,600
| +5% | +$109K | ﹤0.01% | 1953 |
|
|
2023
Q4 | $2.05M | Buy |
95,600
+2,900
| +3% | +$50K | ﹤0.01% | 1937 |
|
|
2023
Q3 | $1.66M | Buy |
92,700
+34,700
| +60% | +$662K | ﹤0.01% | 1973 |
|
|
2023
Q2 | $1.18M | Sell |
58,000
-13,600
| -19% | -$276K | ﹤0.01% | 2371 |
|
|
2023
Q1 | $1.56M | Buy |
+71,600
| New | +$1.74M | ﹤0.01% | 2180 |
|
|
2022
Q3 | – | Sell |
-29,600
| Closed | -$601K | – | 4000 |
|
|
2022
Q2 | $601K | Sell |
29,600
-28,700
| -49% | -$636K | ﹤0.01% | 3048 |
|
|
2022
Q1 | $1.44M | Buy |
58,300
+23,700
| +68% | +$717K | ﹤0.01% | 2468 |
|
|
2021
Q4 | $1.2M | Sell |
34,600
-34,100
| -50% | -$1.08M | ﹤0.01% | 2509 |
|
|
2021
Q3 | $1.86M | Sell |
68,700
-155,600
| -69% | -$3.95M | ﹤0.01% | 2144 |
|
|
2021
Q2 | $5.82M | Sell |
224,300
-6,482
| -3% | -$155K | 0.01% | 1540 |
|
|
2021
Q1 | $4.97M | Buy |
230,782
+96,182
| +71% | +$2.43M | 0.01% | 1651 |
|
|
2020
Q4 | $2.89M | Buy |
134,600
+107,800
| +402% | +$2.62M | ﹤0.01% | 1912 |
|
|
2020
Q3 | $395K | Buy |
+26,800
| New | +$484K | ﹤0.01% | 2902 |
|
|
2020
Q2 | – | Sell |
-293,500
| Closed | -$4.15M | – | 3413 |
|
|
2020
Q1 | $4.15M | Buy |
293,500
+201,100
| +218% | +$3.05M | ﹤0.01% | 1678 |
|
|
2019
Q4 | $1.5M | Buy |
+92,400
| New | +$2.19M | ﹤0.01% | 2449 |
|
|
2018
Q2 | – | Sell |
-59,400
| Closed | -$6.18M | – | 3243 |
|
|
2018
Q1 | $6.18M | Sell |
59,400
-68,100
| -53% | -$7.68M | 0.01% | 1683 |
|
|
2017
Q4 | $12.8M | Buy |
127,500
+29,700
| +30% | +$2.19M | 0.01% | 1227 |
|
|
2017
Q3 | $3.42M | Buy |
+97,800
| New | +$2.64M | ﹤0.01% | 1992 |
|
Other funds holding ANAB
6CM
Jim Simons's ANAB Position: Q2 2026 in Review
Jim Simons reduced its AnaptysBio (ANAB) stake by 36% in Q2 2026, selling an estimated $1.98M and leaving 58,300 shares worth $3.94M. The position accounts for 0.01% of the portfolio, ranked #1585.
Jim Simons first reported a position in ANAB in Q3 2017 and has held it in 27 quarters since. The position peaked at $12.8M in Q4 2017. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.
- Jim Simons held 58,300 shares of AnaptysBio worth $3.94M as of Q2 2026.
- Jim Simons sold 32,600 AnaptysBio shares in Q2 2026, an estimated $1.98M.
- AnaptysBio made up 0.01% of Jim Simons's portfolio in Q2 2026, its #1585 holding.
- Jim Simons first reported a position in AnaptysBio in Q3 2017 and has held it in 27 quarters since.
- Jim Simons's AnaptysBio position peaked at $12.8M in Q4 2017.
- 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.